# Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

> **NCT00712270** · PHASE4 · TERMINATED · sponsor: **Kettering Health Network** · enrollment: 21 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00712270
- **Lead sponsor:** Kettering Health Network
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2008-12
- **Final completion:** 2010-11
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study terminated due to failure to meet sufficient enrollment for valid analysis
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712270, "Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00712270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*